Fenoprofen: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: December 4, 2015🚩 Report this page

Fenoprofen

Propionic Acid Derivatives

Sold as FENOPRON 300

GB MHRA

Drug class: Propionic Acid Derivatives
Availability: See label
Markets covered: 1
Products on record: 1

Overview

Fenoprofen is an active pharmaceutical ingredient in the Propionic Acid Derivatives group (M01AE). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	1	December 4, 2015

GBUnited Kingdom· MHRA

1 product

Uses

GBOfficial regulatory label· revised December 4, 2015[1]

For the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. For the relief of mild/moderate pain.

How to take

Drug interactions

Known interactions involving Fenoprofen. Select one for details. This list is informational and not a complete interaction checker.

Acalabrutinib Aminolevulinic Acid Anisindione Apixaban Ardeparin Avapritinib Betrixaban Cabozantinib Cidofovir Dalteparin Danaparoid Dasatinib Deferasirox Desirudin Diatrizoate Dicumarol Drotrecogin Alfa Edoxaban Enoxaparin Everolimus Fondaparinux Ibritumomab Tiuxetan Ibrutinib Inotersen Iodipamide Iodixanol Iohexol Iopamidol Iopromide Iothalamic Acid Ioversol Ioxilan Ketorolac Leflunomide Lithium Carbonate Lomitapide Methotrexate Mipomersen Omacetaxine Mepesuccinate Panobinostat Pexidartinib Ponatinib Prasugrel Ramucirumab Regorafenib Rivaroxaban Sirolimus Tacrolimus Temsirolimus Teriflunomide Tinzaparin Tositumomab Vorapaxar Warfarin Zanubrutinib Abciximab Acebutolol Acetohexamide Alendronate Aliskiren Alteplase Amikacin Amiloride Amlodipine Anagrelide Anistreplase Argatroban Asparaginase Aspirin Atenolol Azilsartan Balsalazide Baricitinib Bedaquiline Benazepril Bendroflumethiazide Benzthiazide Bepridil Betamethasone Betaxolol Bisoprolol Bivalirudin Brentuximab Vedotin Bromfenac Budesonide Bumetanide Calaspargase Pegol Cangrelor Cannabidiol Caplacizumab Captopril Carteolol Carvedilol Celecoxib Chlorothiazide Chlorpropamide Chlorthalidone Cilostazol Cinoxacin Ciprofloxacin Citalopram Clofarabine Clomipramine Clopidogrel Cyclosporine Daptomycin Defibrotide Deflazacort Delafloxacin Desmopressin Desvenlafaxine Dexamethasone Dexfenfluramine Diclofenac Diflunisal Digoxin Diltiazem Dipyridamole Drospirenone Duloxetine Efavirenz Enalapril Enoxacin Entecavir Eplerenone Epoprostenol Eprosartan Eptifibatide Escitalopram Esmolol Ethacrynate Ethanol Etodolac Exenatide Felodipine Fenfluramine Flucytosine Fludrocortisone Fluoxetine Flurbiprofen Fluvoxamine Fosinopril Furosemide Gatifloxacin Gemifloxacin Gentamicin Glimepiride Glipizide Glyburide Grepafloxacin Heparin Hydralazine Hydrochlorothiazide Hydrocortisone Hydroflumethiazide Ibandronate Ibuprofen Idelalisib Iloprost Indapamide Indomethacin Interferon Beta-1a Interferon Beta-1b Irbesartan Isradipine Kanamycin Ketoprofen Labetalol Lepirudin Levamlodipine Levofloxacin Levomilnacipran Lisinopril Lomefloxacin Losartan Macimorelin Meclofenamic Acid Mefenamate Meloxicam Mesalamine Metformin Methoxsalen Methoxyflurane Methylprednisolone Metolazone Metoprolol Milnacipran Moexipril Moxifloxacin Nabumetone Nadolol Naltrexone Naproxen Nateglinide Nebivolol Netilmicin Nicardipine Nifedipine Nimodipine Niraparib Nisoldipine Norfloxacin Ofloxacin Olmesartan Olsalazine Omega-3 Fatty Acids Oxaliplatin Oxaprozin Pamidronate Paroxetine Pegaspargase Peginterferon Beta-1a Pemetrexed Penbutolol Pentoxifylline Perindopril Phenylbutazone Picosulfurate Pindolol Piroxicam Pitolisant Plazomicin Polythiazide Potassium Bicarbonate Potassium Chloride Potassium Citrate Potassium Gluconate Potassium Iodide Potassium Perchlorate Pralatrexate Prazosin Prednisolone Prednisone Propranolol Quinapril Ramipril Remdesivir Repaglinide Reteplase Risedronic Acid

Showing 240 of 305. Type above to find a specific drug.

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL005510015 · revised December 4, 2015

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised December 4, 2015[1]

Gastrointestinal:
The most commonly observed adverse events are gastrointestinal in nature. 4). 4) have been reported following administration. Less frequently, gastritis has been observed.
Hypersensitivity:
Hypersensitivity reactions have been reported following treatment with NSAIDs. They may consist of (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity comprising asthma, aggravated asthma, bronchospasm or dyspnoea, or (c) assorted skin disorders, including rashes of various types, pruritus, urticaria, purpura, angiodema and more rarely exfoliative and bullous dermatoses (including epidermal necrolysis and erythema multiforme).
Cardiovascular and cerebrovascular:
Palpitations, tachycardia, atrial fibrillation, pulmonary oedema, hypertension, cardiac failure, ECG changes and supraventricular tachycardia have been reported in association with NSAID treatment. 4).
Other adverse events reported less commonly include:
Renal: Nephrotoxicity in various forms, including interstitial nephritis, nephrotic syndrome, papillary necrosis and renal failure. Episodes of dysuria, cystitis and haematuria, oliguria, azotaemia and anuria have occurred.
Hepatic:
Abnormal liver function, hepatitis and jaundice. Increases in alkaline phosphatase, LDH and AST have been observed. 4), depression, confusion, hallucinations, tinnitus, hearing decrease, vertigo, dizziness, nervousness, malaise, fatigue, drowsiness, burning tongue, breast pain, personality change, lymphadenopathy, mastodynia, fever, upper respiratory infection and nasopharyngitis have been reported.
Haematological:
Thrombocytopenia, neutropenia, agranulocytosis, aplastic anaemia and haemolytic anaemia.
Dermatological:
Photosensitivity, pruritus, rash, urticaria, anaphylaxis, Stevens-Johnson syndrome, angioneurotic oedema, increased sweating, exfoliative dermatitis; toxic epidermal necrolysis and alopecia have been reported.

GBOfficial regulatory label· Warnings and precautions· revised December 4, 2015[1]

2, and GI and cardiovascular risks below). 5). 2).
Respiratory disorders:
Caution is required if administered to patients suffering from, or with a previous history of, bronchial asthma since NSAIDs have been reported to precipitate bronchospasm in such patients.
Cardiovascular and cerebrovascular effects:
Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy. Clinical trial and epidemiological data suggest that the use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke).
There are insufficient data to exclude such a risk for Fenopron. Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with Fenopron after careful consideration.
g. hypertension, hyperlipidaemia, diabetes mellitus, smoking).
Cardiovascular, Renal and Hepatic Impairment:
The administration of a NSAID may cause a dose dependent reduction in prostaglandin formation and precipitate renal failure. Patients at greatest risk of this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those taking diuretics and the elderly.
3). Discontinuation of therapy is typically followed by recovery to the pre-treatment state. Some patients have developed elevation of serum transaminase, LDH and alkaline phosphatase and it is recommended that fenoprofen be discontinued if any significant liver abnormalities occur.
Borderline elevations of one or more liver function tests may occur in up to 15% of patients. Severe hepatic reactions, including jaundice and cases of fatal hepatitis, have been reported. Patients in whom an abnormal liver test has occurred should be evaluated for evidence of more severe hepatic reactions.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drug interactions

Drugs in the same class

Sources & citations